Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.
about
Finasteride for benign prostatic hyperplasiaDrug-related problems in patients with benign prostatic hyperplasia: a cross sectional retrospective studyDropout in a longitudinal, cohort study of urologic disease in community men.A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men.Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis.Prevalence of Lower Urinary Tract Symptoms in China, Taiwan, and South Korea: Results from a Cross-Sectional, Population-Based Study.The diagnosis of benign prostatic obstruction: Development of a clinical nomogram.Genetic alterations in benign prostatic hyperplasia patients.
P2860
Q24234464-A8DC502B-D862-4316-A91F-C96B6D42CDE9Q28539178-327ECE66-6B1D-4878-B5C2-D995E22512CBQ33266615-14CB91E5-96C7-4E7E-AEEA-3392BA5795FFQ33320106-56A46167-93D8-4D76-A86F-3FC741F3E86DQ35816476-4B63D18F-6E87-4516-BBC3-CC3D06ED432DQ35964540-18186B66-61DC-4798-BC4F-5FD5604D6A06Q36116528-76B1FFC5-CBFC-452F-9C19-B3C497D48048Q37192948-2533344C-5ECD-4AAD-BE34-E7089DD7140CQ37323301-8E84903B-AD1F-421F-9BB2-A79347595DAAQ38111255-07C25FCE-46F5-47CE-B95E-A6528E28CC2BQ38374354-D22B54E2-86AF-4CAF-8EBD-54F69558475BQ41669814-FFCD4768-FA5E-428D-87BE-FF03A2954853Q47095728-BFD9B3B4-87DA-4AB4-95A2-1DD93661DA6C
P2860
Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Storage (irritative) and voidi ...... gression and related outcomes.
@en
Storage
@nl
type
label
Storage (irritative) and voidi ...... gression and related outcomes.
@en
Storage
@nl
prefLabel
Storage (irritative) and voidi ...... gression and related outcomes.
@en
Storage
@nl
P2093
P1433
P1476
Storage (irritative) and voidi ...... gression and related outcomes.
@en
P2093
Amy O Johnson-Levonas
Brian Saltzman
Claus G Roehrborn
Donald Bergner
Joanne Waldstreicher
John D McConnell
PLESS Study Group. Proscar Long-term Efficacy and Safety Study
Perinchery Narayan
Thomas J Cook
P356
10.1016/S0302-2838(02)00210-5
P407
P577
2002-07-01T00:00:00Z